These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25340423)

  • 21. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic mutations of PIK3CA in human cancers.
    Samuels Y; Velculescu VE
    Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
    Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
    J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
    Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
    Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
    Yuan W; Stawiski E; Janakiraman V; Chan E; Durinck S; Edgar KA; Kljavin NM; Rivers CS; Gnad F; Roose-Girma M; Haverty PM; Fedorowicz G; Heldens S; Soriano RH; Zhang Z; Wallin JJ; Johnson L; Merchant M; Modrusan Z; Stern HM; Seshagiri S
    Oncogene; 2013 Jan; 32(3):318-26. PubMed ID: 22370636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
    Sabbah DA; Vennerstrom JL; Zhong HA
    J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
    Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
    Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
    Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
    Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.
    Mankoo PK; Sukumar S; Karchin R
    Proteins; 2009 May; 75(2):499-508. PubMed ID: 18951408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
    Wang J; Kuropatwinski K; Hauser J; Rossi MR; Zhou Y; Conway A; Kan JL; Gibson NW; Willson JK; Cowell JK; Brattain MG
    Mol Cancer Ther; 2007 Mar; 6(3):1143-50. PubMed ID: 17363507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct epithelial-to-mesenchymal transitions induced by
    Gjelaj E; Hamel PA
    J Cell Sci; 2021 Feb; 134(4):. PubMed ID: 33526718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
    Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
    Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.